Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab.

Anton E AnderssonBarbro LinderholmDaniel Giglio

Published in: Acta oncologica (Stockholm, Sweden) (2020)

Measuring changes in NTproBNP may be used to monitor patients for TIC under trastuzumab therapy. Patients with a cardiovascular risk profile are more at risk of developing TIC.

Keyphrases

positive breast cancer
end stage renal disease
obsessive compulsive disorder
ejection fraction
newly diagnosed
epidermal growth factor receptor
prognostic factors
peritoneal dialysis
metastatic breast cancer
stem cells
patient reported outcomes
bone marrow
smoking cessation
replacement therapy